The addition of pembrolizumab (Keytruda) to platinum-based chemotherapy led to an investigator-assessed objective response rate (ORR) of 39.4% (95% CI, 22.9%-57.9%) as frontline therapy in patients with advanced penile squamous cell carcinoma…
Pembrolizumab Plus Chemotherapy Shows Preliminary Activity in Advanced Penile Cancer
